Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dyax’s HAE Candidate Meets Clinical Endpoints In Phase III Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

With the completion of Phase III testing, Dyax plans to submit final piece of rolling BLA for DX-88 in early fourth quarter.

You may also be interested in...



Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review

Firm is presenting a risk management plan addressing hypersensitivity and anaphylaxis, but efficacy results for Kalbitor (ecallantide) will also be a key discussion topic.

Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review

Firm is presenting a risk management plan addressing hypersensitivity and anaphylaxis, but efficacy results for Kalbitor (ecallantide) will also be a key discussion topic.

Dyax Completes Rolling BLA For HAE Candidate DX-88

Company seeks priority review, which if granted could set an FDA action date in March.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel